Compared with other DOACs, rivaroxaban linked to higher rates of GI bleeding overall and in an analysis restricted to patients with atrial fibrillation
Your search for dabigatran returned 9 results
Investigators found an incremental increase in risks from oral anticoagulants as kidney function decreased, highlighting the need for more research to better understand bleeding risk and net benefit of treatment in the CKD population.
No substantial differences seen for other outcomes or for other direct oral anticoagulant comparisons
Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels
Although more research is needed, data suggest that the cardioprotective effect of direct oral anticoagulants may extend to patients with advanced CKD.
Findings may help with decision-making in this high-risk patient population.
Disparities seen among VA patients both for initiating any anticoagulant therapy and for initiating direct-acting oral anticoagulant use
Risks for ischemic stroke or systemic embolism, major bleeding events lower with DOACs overall as a class versus warfarin
Pradaxa oral pellets are supplied in child-resistant packets in 20mg, 30mg, 40mg, 50mg, 110mg, and 150mg dosage strengths.